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ORIGINAL INVESTIGATION
Nicorandil attenuates carotid intimal 
hyperplasia after balloon catheter injury 
in diabetic rats
Ying Qian Zhang, Feng Tian, Ying Zhou, Yun Dai Chen*, Bo Li, Qiang Ma and Ying Zhang
Abstract 
Background: Diabetic patients suffer from undesired intimal hyperplasia after angioplasty. Nicorandil has a trend to 
reduce the rate of target lesion revascularization. However, whether nicorandil inhibits intimal hyperplasia and the 
possible mechanisms underlying it remain to be determined. We aimed at assessing the effect of nicorandil on intimal 
hyperplasia in diabetic rats.
Methods: After intraperitoneal injection of streptozotocin (STZ, 50 mg/kg), balloon injury model was established in 
carotid arteries of diabetic rats. Rats were randomized to vehicle, nicorandil (15 mg/kg/day) or 5-hydroxydecanoate 
(5-HD, 10 mg/kg/day), a mitochondrial ATP-sensitive potassium channel (mitoKATP channel)-selective antagonist. 
Perivascular delivery of εPKC siRNA was conducted to determine the role of εPKC pathway in intimal hyperplasia. In 
hyperglycemia environment (25 mM glucose), primary culture of vascular smooth muscle cells (VSMCs) were treated 
with nicorandil or 5-HD. Cell proliferation and cell migration were analyzed.
Results: Intimal hyperplasia significantly increased 14 days after balloon injury in diabetic rats (p < 0.01). Nicorandil 
inhibited intima development, reduced inflammation and prevented cell proliferation in balloon-injured arteries 
(p < 0.01). The protective effects of nicorandil were reversed by 5-HD (p < 0.05). εPKC was activated in balloon-injured 
arteries (p < 0.01). Nicorandil inhibited εPKC activation by opening mitoKATP channel. Perivascular delivery of εPKC 
siRNA inhibited intimal hyperplasia, inflammation and cell proliferation (p < 0.01). High glucose-induced VSMCs 
proliferation and migration were inhibited by nicorandil. εPKC activation induced by high glucose was also inhibited 
by nicorandil and that is partially reversed by 5-HD. εPKC knockdown prevented VSMCs proliferation and migration 
(p < 0.01).
Conclusions: Our study demonstrates that nicorandil inhibits intimal hyperplasia in balloon-injured arteries in dia-
betic rats. Nicorandil also prevents VSMCs proliferation and migration induced by high glucose. The beneficial effect 
of nicorandil is conducted via opening mitoKATP channel and inhibiting εPKC activation.
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Background
Intimal hyperplasia occurs after percutaneous coronary 
intervention (PCI) or percutaneous transluminal coro-
nary angioplasty (PTCA). It is the pathologic basis for 
restenosis. Diabetes mellitus (DM) promotes intimal 
hyperplasia via increased inflammation, proliferation, 
and oxidative stress in lesions [1] and results in higher 
risk of restenosis [2]. Nicorandil is a hybrid agent with 
ATP-sensitive potassium channel (KATP) channel opener 
and nitrate properties. Retrospective trials reveal that in 
patients underwent PCI or PTCA, nicorandil reduces the 
rate of target vessel revascularization (TVR) [3]. In dia-
betic patients, a trend toward lower target lesion revas-
cularization (TLR) was observed in nicorandil treated 
group [4]. Besides, nicorandil has been found to stabilize 
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coronary plaque [5] and reduce coronary artery disease 
mortality [6] in patients with stable angina.
Intimal hyperplasia is characterized by vascular smooth 
muscle cell (VSMC) proliferation, inflammatory cell infil-
tration, endothelial cell injury and augmented position 
of extracellular matrix. εPKC regulates VSMC prolifera-
tion and migration in vitro and is involved in the devel-
opment of intimal hyperplasia in vivo [7]. A recent study 
finds that hyperpolarization of mitochondrial membrane 
potential (ΔΨm) promotes VSMCs proliferation and inti-
mal hyperplasia [8] in several preclinical animal models. 
Nicorandil is KATP channel opener. It directly opens the 
mitochondrial KATP channel (mitoKATP channel) and 
depolarizes ΔΨm [9, 10]. Chronic hyperglycemia leads to 
an increase in PKC activation that could promote VSMCs 
growth and mediates restenosis [1]. In rat myocardial 
infarction model, nicorandil inhibits εPKC activation by 
opening the mitoKATP channel [11]. Nicorandil has also 
been found to inhibit oxidative stress [12] and attenuate 
inflammation [13]. However, whether nicorandil inhibits 
intimal hyperplasia after balloon catheter injury in dia-
betic rats remains to be determined.
In the present study, we hypothesizes that nicorandil 
inhibits intimal hyperplasia in diabetic rats through 
opening mitoKATP channel and inhibiting εPKC activa-
tion. An in  vivo carotid balloon catheter injury model 
and in vitro primary cultured VSMCs were used to inves-
tigate this hypothesis.
Methods
Induction of diabetes and rat balloon catheter injury 
model
The animal experiments were approved by Animal 
Research Committee of Chinese PLA General Hospi-
tal. All experiments were conducted in accordance with 
the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH 
Publication No.85-23, revised 1996). Male Sprague-Daw-
ley (SD) rats (n =  60, 150–180  g) were purchased from 
Experimental Animal Center of Chinese PLA General 
Hospital (approval No. SCXK 20120001). All animals 
were housed in a 12 h light/dark cycle room at controlled 
temperature (23  ±  2  °C) and humidity (50–60  %) with 
a free access to food and water. All rats were fed with 
regular rodent chow for the first week. After 2 weeks of 
high fat diet (85 % standard diet, 8 % animal fat, 2 % total 
cholesterol, 5  % glucose), DM was induced by a single 
intraperitoneal injection of citrate buffer vehicle (0.1 M, 
pH 4.5) with streptozotocin (50  mg/kg; Sigma-Aldrich, 
St Louis, MO, USA). The diabetic model was confirmed 
after 72  h by random blood glucose  >16.7  mmol/L [1]. 
The balloon catheter injury model was created with a 2F 
Fogarty catheter (Edwards Lifesciences, Irvine, CA) in the 
left common carotid artery as previously described [14]. 
Briefly, rats were anesthetized by intraperitoneal injec-
tion of pentobarbital (50 mg/kg, Sigma-Aldrich, St Louis, 
MO, USA). The left external carotid artery was exposed. 
Then the balloon was introduced through the left exter-
nal carotid artery into the common carotid artery. The 
common carotid artery was denudated by passing the 
inflated balloon through the lumen three times. After 
removal of the catheter, the punched area was sealed, and 
the common carotid artery resumed blood flow.
Sham group (n = 8) was conducted with an uninflated 
balloon and treated by gavage feeding with vehicle. Bal-
loon injury group (n = 10) was treated by gavage feeding 
with vehicle from the 1st day after balloon injury. Nico-
randil group (n = 10) was treated by gavage feeding with 
nicorandil (15  mg/kg/day, Chugai Pharmaceutical Co., 
Japan) from the 1st day after balloon injury. 5-hydroxyde-
canoate (5-HD; Sigma-Aldrich, St Louis, MO, USA), a 
mitoKATP channel-selective antagonist was used to detect 
the role of mitoKATP channel. Nicorandil and 5-HD group 
(n =  10) was treated by gavage feeding with nicorandil 
and 5-HD (10 mg/kg/day) from the 1st day after balloon 
injury. 14 days after balloon injury, rats were killed with 
excessive anesthesia and the left common carotid arteries 
were subjected to following studies.
Histology
Carotid arteries were fixed in 4  % paraformaldehyde, 
dehydrated and embedded in paraffin. 5-μm thick sec-
tions were prepared. Serial three cross sections were cut 
from each artery and stained with Elastica van Gieson 
to observe the elastic laminae and intimal hyperplasia. 
Intima, media and adventitia cross-sectional areas were 
measured by software Image J 1.49. The intima area was 
calculated by subtracting the lumen area from the area 
defined by the internal elastic lamina (IEL). The media 
area were calculated by subtracting the area defined 
by the IEL from the area defined by the external elastic 
lamina (EEL) [15]. VSMCs proliferation was detected 
by immunofluorescent (IF) staining of proliferating cell 
nuclear antigen (PCNA; Cell Signaling Technology, MA, 
USA, 1:200) and alpha smooth muscle actin (α-SMA, 
Abcam, Cambridge, UK, 1:200). Inflammation was 
detected by immunohistochemistry (IHC) staining of 
CD68 (Abcam, Cambridge, UK, 1:200).
In vitro VSMCs culture and high glucose treatment
VSMCs was isolated from rat aorta and cultured in 
DMEM containing 5.5  mM glucose supplemented with 
10 % FBS at 37 °C under 5 % CO2 in a humidified incu-
bator. VSMCs were identified by staining with  α-SMA. 
The 3rd to 5th passages were used for experiments. To 
mimic the hyperglycemia environment, VSMCs cultured 
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in 5.5 mM glucose were serum starved for 24 h and then 
incubated in 25  mM glucose culture medium [1]. To 
determine the effect of nicorandil and mitoKATP chan-
nel on VSMCs, nicorandil (100  μM, Sigma-Aldrich, St 
Louis, MO, USA) and 5-HD (500  μM, Sigma-Aldrich, 
St Louis, MO, USA) were used in cell culture. In control 
group, VSMCs were incubated in 5.5  mM glucose cul-
ture medium containing 1 % FBS for 24 h. In high glucose 
group, VSMCs were incubated in 25 mM glucose culture 
medium containing 1  % FBS for 24  h. In high glucose-
nicorandil group, VSMCs were incubated in 25 mM glu-
cose culture medium containing 100 μM nicorandil and 
1  % FBS for 24  h. In high glucose-nicorandil-5HD co-
treatment group, 500 μM 5-HD diluted in 25 mM glucose 
culture medium was given 30 min earlier than nicorandil.
Small interfering RNA transfection in vitro and in vivo
Perivascular delivery of εPKC siRNA was conducted as 
previously described [16, 17]. In-vivo ready εPKC siRNA 
(NM_017171.1), (#AM16830, ThermoFisher, Wilming-
ton, DE) were premixed with lipofectamine rnaimax (Life 
Technologies, NY) and optimem (Invitrogen, Carlsbad, 
CA) to a total volume of 60 μl, and then mixed with 80 μl 
4  % pluronic gel (Sigma-Aldrich, St Louis, MO, USA). 
Following dissecting the carotid artery from the con-
necting tissue and conducting the balloon injury, 140 μl 
ice-cold mixed pluronic gel containing either scramble 
siRNA (100 μg) or εPKC siRNA (100 μg) applied to the 
carotid artery. The incision was sutured after the applica-
tion of the gel. The scramble siRNA group (n = 10) and 
εPKC siRNA group (n = 10) were removed 14 days after 
the balloon injury. For the transfection of εPKC siRNA 
(NM_017171.1), (#AM16708, ThermoFisher, Wilming-
ton, DE) and non-targeted siRNA in  vitro, VSMCs at 
60 % confluence were transfected at the concentration of 
25  nM using lipofectamine rnaimax (Life Technologies, 
NY) according to the manufacture’s instruction. 48  h 
after siRNA transfection, CMECs were harvested for fur-
ther experiments.
Cell proliferation and migration
Cell proliferation was determined by a modified 
3-(4,5-dimethyl-thiazol-2-yl)-2,5-dyphenyltertrazolium 
bromide (MTT) assay (Sigma-Aldrich, St Louis, MO, 
USA) and BrdU Cell Proliferation Assay Kit (Cell Sign-
aling Technology, MA, USA). VSMC migration was 
analyzed by wound healing assay. VSMCs (50–70  % 
confluence) were wounded uniformly by using 1.15 mm 
diameter pipette tip. 24 h later, standard photographs of 
the wound areas were taken by a phase contrast micros-
copy (Olympus Corporation, Tokyo, Japan). Distance 
between cells of the wound was calculated by subtracting 
the distance at the lesion edge at 24  h from that at 0  h 
[18].
εPKC translocation in  vivo and in  vitro was assessed 
by western blot. Carotid arteries were frozen in liq-
uid nitrogen and stored at −80 °C until western blot. In 
brief, arteries were homogenized in cold buffer (50 mM 
Tris-HCl (pH 7.4), 5 mM EDTA, 10 mM EGTA, 50 mM 
NaF, 50  μg/ml phenylmethylsulfonyl fluoride, and 0.3  % 
β-mercaptoethanol). The supernatant centrifugated 
at 1000g for 10  min was recentrifuged at 100,000g for 
60 min at 4  °C. The 100,000g supernatant was the cyto-
solic fraction. Particulate fractions were obtained by 
treating the 100,000g pellet with 3  % Triton X-100 and 
recentrifugation at 10,000g for 10  min [19]. In VSMCs, 
cells were collected, homogenized in homogenization 
buffer (20 mM Tris-HCl (pH 7.4), 2 mM EDTA,10 mM 
EGTA, 250  mM sucrose, 1×  phosphatase inhibitor 
cocktail (Cell Signaling Technology, MA, USA). Cell 
homogenates were centrifuged at 100,000g for 30  min 
and supernatants were collected as soluble samples. The 
pellets were homogenized with homogenization buffer 
containing 1  % Triton X-100 and recentrifugation at 
10,000g for 30 min. The supernatants are particulate frac-
tions which is activated εPKC [7]. Cytosolic and particu-
late fractions were separated by SDS-PAGE, transferred 
to polyvinylidene difluoride membranes, and probed 
with antibodies for εPKC (Santa Cruz, CA, USA). The 
primary antibodies at the concentration of 1:1000 were 
exposed for overnight at 4 °C. Next, horseradish peroxi-
dase-conjugated secondary antibodies (Beyotime, China) 
at the concentration of 1:5000 were added, and incubated 
for 1 h at 37 °C. The membranes were then developed by 
enhanced chemiluminescence (Beyotime, China). The 
same membranes were reprobed with antibody for actin 
(Beyotime, China). The blotting film was quantified using 
a scanner and a densitometry program (Image J).
Statistical analysis
Data were presented as mean  ±  SE. The statistic soft-
ware package SPSS 13.0 was used for analysis of data. 
Statistical comparisons were performed using the paired, 
two-tailed Student’s t test for experiments consisting of 
two groups only. One-way ANOVA with post hoc test-
ing were used for experiments consisting of more than 
two groups. If normality test failed, Kruskal–Wallis with 
Dunn’s post hoc test was used. Results were considered 
statistically significant when p < 0.05.
Results
Carotid balloon injury is established in DM rats
Two rats with random blood glucose were excluded 
3 days after STZ injection. The balloon injury procedure 
Page 4 of 16Zhang et al. Cardiovasc Diabetol  (2016) 15:62 
was performed at the 3rd day after STZ injection and was 
well tolerated by the diabetic rats. All animals survived 
the study period. There were no significant differences 
between chow intakes of different groups (Fig. 1a). Body 
weight and blood glucose were measured before STZ 
injection, at the 3rd day and 17th day after STZ injec-
tion, respectively. Blood glucose levels in STZ-injection 
rats increased 3  days after STZ injection and remained 
higher than 16.7  mmol/L. Nicorandil had no significant 
influence on body weight or glucose levels (p  >  0.05) 
(Fig. 1b, c).
Nicorandil attenuates intimal hyperplasia
As reported earlier, intimal hyperplasia developed in 
carotid arteries 14 days after balloon injury [17, 20]. A sig-
nificant increase of intimal hyperplasia was observed in the 
DM-injury group (intima/media (I/M) ratio 1.59 ±  0.28; 
intimal area 11.49  ±  2.05  ×  104  μm2; lumen area 
3.37 ± 0.72 × 104 μm2) compared with the DM-sham group 
(I/M ratio 0.02 ± 0.01; intimal area 0.12 ± 0.05 × 104 μm2; 
lumen area 14.91  ±  2.01  ×  104  μm2, p  <  0.01). Nico-
randil significantly reduced intimal hyperplasia (I/M ratio 
0.62 ±  0.10; intimal area 4.52 ±  0.48 ×  104  μm2; lumen 
Fig. 1 Chow intake, body weight and blood glucose in each group. a Chow intakes in different groups. No significant difference was observed 
among different groups. Bars represent mean ± SE. b Body weight in sham operation group (DM-sham group, n = 8), balloon injury group (DM-
injury group, n = 10), nicorandil-treated balloon injury group (DM-injury + nicorandil group, n = 10), and nicorandil and 5-HD-treated group 
(DM-injury + nicorandil + 5HD group, n = 10). c Blood glucose in DM-sham group, DM-injury group, DM-injury + nicorandil group, and DM-
injury + nicorandil + 5HD group. No significant difference was observed among different groups. Blood glucose significantly increased after STZ 
injection. Bars represent mean ± SE. **p < 0.01
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area 9.78 ± 1.35 × 104 μm2, p < 0.01) compared with the 
DM-injury group. 5-HD, the mitoKATP channel-selective 
antagonist, induced more prominent intimal proliferation 
(I/M ratio 0.88 ± 0.22; intimal area 6.27 ± 0.53 × 104 μm2; 
lumen area 7.27 ± 0.97 × 104 μm2, p < 0.05) than that in 
the DM-injury + nicorandil group (Fig. 2a–d). There were 
no significant differences between media areas of different 
groups (Fig. 2e).
Nicorandil alleviates inflammation and proliferation
Inflammatory cell infiltration is a key element in inti-
mal hyperplasia after vascular injury [21]. Inflammation 
was assessed by IHC staining of CD68, a specific surface 
marker of macrophage. We observed a dramatic decrease 
in the number of CD68-positive cells in response to 
nicorandil treatment (2.42  ±  1.32 vs. 22.23  ±  3.63, 
p  <  0.01). Additional treatment of 5-HD (10.34 ±  4.23, 
p  <  0.01) significantly increased macrophage infiltra-
tion in intima compared with the DM-injury  +  nico-
randil group (Fig. 3a, b). The rate of PCNA-positive cells 
was significantly lower in the DM-injury  +  nicorandil 
group (3.71  ±  0.85  %) than that in DM-injury group 
(24.6  ±  3.23  %, p  <  0.01). The proliferation VSMCs in 
intima were evaluated by PCNA and α-SMA staining. 
VSMCs account for 93.6 ±  1.72  % of the ultimate inti-
mal proliferation. The decrease of PCNA-positive cells 
induced by nicorandil was partially reversed by 5-HD 
pretreatment (9.03 ± 1.67 %, p < 0.01) (Fig. 4a, b). 
Nicorandil inhibits VSMCs proliferation and migration 
induced by high glucose
To investigate the mechanisms of therapeutic potential 
of nicorandil on intimal hyperplasia after balloon injury 
in diabetic models, VSMCs isolated from thoracic aorta 
were used. Cell proliferation was demonstrated by BrdU 
and MTT assay. Nicorandil prevented cell proliferation 
induced by high glucose. Pretreatment of 5-HD alleviated 
the decrease of cell proliferation induced by nicorandil 
(Fig.  5a, b). These results demonstrated that nicorandil 
suppressed VSMCs proliferation and cell viability by 
opening mitoKATP channel. VSMCs migration also con-
tributes to intima hyperplasia after arterial injury [22]. 
A wound healing assay was performed in VSMCs stim-
ulated with high glucose. Cell migrated more slowly in 
the present of nicorandil 24  h post high glucose stimu-
lation (54.50 ± 3.91 vs. 82.32 ± 2.33 %, p < 0.01). 5-HD 
increased the migrated area (68.35  ±  2.04  %, p  <  0.01) 
compared with the nicorandil treated group (Fig. 5c, d).
εPKC is activated in intimal hyperplasia in balloon‑injured 
arteries
It has been reported that chronic hyperglycemia leads to 
PKC activation [1]. Recent study reveals that sustained 
inhibition of εPKC inhibits intimal hyperplasia in rat 
models [7]. Thus, we investigated whether nicorandil 
inhibited εPKC activation in injured arteries in diabetic 
rats. εPKC translocation (movement from cell solu-
ble to cell particulate fraction) is an established method 
to assess εPKC activation. We found that carotid bal-
loon injury in diabetic rats stimulated εPKC activation, 
and this activation was partly blocked by gavage feeding 
with nicorandil. Furthermore, 5-HD partly reversed the 
blockage exhibited by nicorandil (Fig.  6a, b). εPKC was 
knockdown by perivascular delivery of εPKC siRNA, 
and the silencing efficiency was determined by western 
blot. εPKC expression in εPKC siRNA delivered group 
was reduced to 30.41  ±  5.17  % of that in the scramble 
siRNA delivered group (Fig.  6c, d). Intimal hyperpla-
sia was significantly inhibited when εPKC siRNA was 
perivascular delivered immediately after carotid injury. 
Lumen area increases from 3.41  ±  0.62  ×  104  μm2 to 
7.80 ± 1.08 × 104 μm2 (p < 0.01) after εPKC knockdown. 
I/M ratio was lower in the εPKC siRNA delivered group 
(0.82 ± 0.10) than that in the scramble siRNA delivered 
group (1.62 ± 0.54, p < 0.01) (Fig. 6e–g).
εPKC activation results in inflammation and proliferation
Localized εPKC knockdown with targeted siRNA 
resulted in significant fewer CD 68-positive cells in 
intima than that in the scramble siRNA delivered group 
(8.14  ±  1.31 vs. 20.39  ±  3.75, p  <  0.01) (Fig.  7a, b). IF 
staining of PCNA and α-SMA also show a decrease in 
PCNA-positive cells in intima in the εPKC siRNA deliv-
ered group (8.41 ± 1.56 % vs. 23.78 ± 3.45 %, p < 0.01) 
(Fig. 7c, d).
εPKC regulates VSMCs proliferation and migration
In previous experiments, high glucose induced εPKC 
translocation in primary cultured VSMCs [1]. In our 
present study, εPKC activation is partially blocked by 
nicorandil in  vitro (Fig.  8a, b). Knockdown of εPKC 
was achieved 48  h after siRNA transfection. εPKC pro-
tein in high-glucose-εPKC siRNA group was reduced 
to 24.94  ±  7.67  % of that in high-glucose-scramble 
siRNA group (Fig.  8c, d). VSMCs migration stimulated 
by 24  h high glucose was significantly inhibited in the 
εPKC knockdown cells (79.42 ± 5.14 vs. 52.40 ± 4.66 %, 
p  <  0.01) (Fig.  8e, f ). Besides, cell proliferation and cell 
viability were also decreased in εPKC knockdown 
VSMCs, compared with the scramble siRNA transfected 
group (Fig. 9a, b). 
Discussion
In this study, we have demonstrated that nicorandil atten-
uates intimal hyperplasia and inflammation infiltration 
in arterial lesions in diabetic rats, and this is mediated 
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Fig. 2 Intimal hyperplasia 14 days after balloon injury. a Cross sections of carotid arteries from diabetic rats 14 days after balloon injury. Sections 
were stained with Elastica van Gieson. b Quantitative analysis of intima area. c Quantitative analysis of intima/media area ratio. d Quantitative analy-
sis of lumen area. e Quantitative analysis of media area in DM-sham group, DM-injury group, DM-injury + nicorandil group, and DM-injury + nico-
randil + 5HD group. Nicorandil reduced the intima area and intima/media ratio, and it increased lumen area. The protective effect of nicorandil was 
significantly blocked by 5-HD. No significant difference was seen in media areas of different groups. Bars represent mean ± SE. **p < 0.01, *p < 0.05
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by mitoKATP channel and εPKC pathway. Furthermore, 
our data indicates that nicorandil inhibits high glucose-
induced VSMCs proliferation and migration. Our study 
may provide a better understanding about the effects of 
nicorandil on vascular injury in diabetic models.
Higher rate of restenosis is seen in diabetic patients 
compared to patients without diabetes after PCI [23]. 
Intimal hyperplasia arises from an initial injury to the 
artery. Diabetes enhances cellular proliferation, adhesion 
molecular expression and inflammatory cell infiltration 
after arterial injury in multiple animal models [24]. Dia-
betic rats respond to vascular injury with increased influx 
of inflammatory cells, enhanced proliferative activity and 
greater intima formation compared with non diabetic 
rats [25]. In vitro, high glucose promotes VSMCs migra-
tion and proliferation by increasing integrins, advanced 
glycation end products and glycoproteins [24]. Several 
anti-diabetic therapies have been found to inhibit inti-
mal hyperplasia after balloon injury in preclinical model. 
Insulin detemir inhibits intimal hyperplasia after balloon 
catheter injury in Zucker Fatty rats [26]. Glucagon-like 
peptide-1(GLP-1)-based anti-diabetic agents, such as 
Dipeptidyl peptidase-4 inhibitor linagliptin [27], GLP-1 
receptor agonist Exenatide [28], and GLP-1 analogue 
Liraglutide [29], have revealed their tissue-protective 
potentials. However, neutral protamine Hagedorn insulin 
Fig. 3 Inflammatory cell infiltration in injured carotid arteries. a IHC staining of CD 68 in DM-sham group, DM-injury group, DM-injury + nicorandil 
group, and DM-injury + nicorandil + 5HD group. b Quantitative analysis of CD 68-posotive cells per 104 μm2. Nicorandil decreased CD 68-positive 
macrophages in balloon injured arteries. This decrease was reversed by 5-HD. Bars represent mean ± SE. **p < 0.01
(See figure on next page.) 
Fig. 4 Cell proliferation in injured carotid arteries. a IF staining of PCNA and α-SMA in DM-sham group, DM-injury group, DM-injury + nicorandil 
group, and DM-injury + nicorandil + 5HD group. b Quantitative analysis of percentage of PCNA-positive cells in intima. Nicorandil decreased cell 
proliferation in balloon injured arteries. This decrease was reversed by 5-HD. Bars represent mean ± SE. **p < 0.01
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does not inhibits intimal hyperplasia [26]. Potential ther-
apies aimed at prevention of intimal hyperplasia are still 
needed. Nicorandil is a hybrid agent with ATP-sensitive 
potassium channel (KATP) channel opener and nitrate 
properties. It is a widely used anti-angina agent and has 
shown vascular-protective effect in several clinical stud-
ies. Clinical study suggests that nicorandil reduces the 
rate of TVR [3]. Oral nicorandil also stabilizes coronary 
plaque in patients with stable angina pectoris [5]. A trend 
toward lower TLR was shown in diabetic patients under-
going PCI in a randomized control trial [4]. Coupled with 
the observation in these clinical studies, we observe that 
nicorandil significantly decreases intimal hyperplasia 
14  days after balloon injury in diabetic rats. Nicorandil 
increases lumen area and decreases intima/media ratio 
and intima area after balloon injury in diabetic rats. Nic-
orandil also inhibits cell proliferation and macrophage 
infiltration in arterial lesions after 14  days of balloon 
injury. VSMCs account for 93.6 ± 1.72 % of the ultimate 
intimal proliferation. Previous experiments reported that 
nicorandil inhibited SMCs proliferation in rat pulmonary 
arterial hypertension model and attenuated LPS-induced 
inflammation [13]. Our data suggest that nicorandil 
reduces the rate of restenosis by inhibiting cell prolifera-
tion, reducing inflammation cell infiltration and attenuat-
ing the intimal hyperplasia after balloon injury in diabetic 
rats. In our preliminary experiment, we investigated the 
effect of nicorandil on intimal hyperplasia in non-DM 
rats. Nicorandil inhibits intimal hyperplasia after bal-
loon injury in non-DM rats, but the differences of lumen 
area and I/M ratio between non-DM-injury group and 
non-DM-injury-nicorandil group are of no statistical sig-
nificance (data shown in Additional file 1: Figure S1). The 
reason is that non-DM rats developed less intima than 
diabetic rats after balloon injury. With more predomi-
nant intima in DM rats, nicorandil exhibits inhibitive 
effect on intimal hyperplasia.
Previous studies on nicorandil in diabetic animals 
yields conflicting results. 15  mg/kg/day nicorandil has 
no effect on plasma glucose and body weight in STZ-
induced diabetic rats [12]. 30 mg/kg/day nicorandil does 
not affect the blood glucose or body weight in STZ-
injected mice [30]. 15 mg/kg/day nicorandil decreases the 
fast blood glucose and increases body weight, although 
this difference is not statistically significant [31]. When 
0.003  % nicorandil-containing-diet is given 2  days after 
STZ injection, body weight loss and blood glucose level 
were significantly lower than those of STZ-injected rats. 
However, when nicorandil is given 3 or 4 days after STZ 
injection, no significant difference is observed between 
nicorandil treatment group and STZ-injected group [32]. 
In our preliminary study, nicorandil was given at the dose 
of 5 or 15 mg/kg/day from the 3rd day after STZ injec-
tion. 15  mg/kg/day nicorandil significantly inhibits inti-
mal hyperplasia and is used in the later experiments. In 
the present study, 15  mg/kg/day nicorandil has no sig-
nificant influence on body weight or glucose levels. The 
inhibition effect on intimal hyperplasia exhibited by nico-
randil is not achieved through glycermic control.
Several lines of evidence suggest that high glucose 
per se promoted VSMCs proliferation and exaggerated 
intimal hyperplasia [1, 20]. In the present study, 24 h of 
high glucose treatment induces VSMCs proliferation 
and migration in the presence of 1  % serum. High glu-
cose has been found to induce hyperpolarization of ΔΨm 
in  vitro [20]. A recent study found that hyperpolariza-
tion of ΔΨm promotes VSMCs proliferation and intimal 
hyperplasia [8]. Nicorandil directly opens the mitoKATP 
channel and depolarize ΔΨm [9, 10]. To investigate the 
role of mitoKATP channel in the inhibition effect of nico-
randil on intimal hyperplasia, 5-HD was used in vivo and 
in vitro. In vivo study reveals that 5-HD partially reverses 
the inhibition effect of nicorandil on intimal hyperplasia. 
Inflammation cell infiltration and proliferation inhibited 
by nicorandil was partially blocked by 5-HD. Inhibition 
effect of nicorandil on VSMCs proliferation and migra-
tion is also significantly blocked by pretreatment of 
5-HD in  vitro. Taken together, nicorandil inhibits inti-
mal hyperplasia, inflammation, VSMCs proliferation and 
migration by opening mitoKATP channel.
PKC family consists of 11 related serine/threonine pro-
tein kinases. The importance of PKC signaling for VSMCs 
growth and restenosis has been shown previously. αPKC 
and εPKC, together with atypical PKCs, mediated cell 
proliferation and survival [33]. Sustained inhibition of 
εPKC inhibited intimal hyperplasia in vivo and prevented 
(See figure on previous page.) 
Fig. 5 Effect of nicorandil on high-glucose-induced VSMCS proliferation and migration. a VSMCs were incubated with high glucose (25 mM) and 
treated with nicorandil (100 μmol/l) or 5-HD (500 μmol/l). VSMCs proliferation was detected using BrdU proliferation assay kit. 24 h of high glucose 
induced VSMCs proliferation. Nicorandil inhibited the proliferation and 5-HD partially blocked the effect of nicorandil. b Cell viability was assessed 
by MTT assay kit. Nicorandil suppressed the increase of cell viability induced by high glucose. 5-HD, a mitoKATP channel-selective antagonist, 
blocked the effect of nicorandil. c VSMCs migration was assessed by wound healing assay. d Quantitative analysis of percentage of migrated area 
in control group, high glucose group, high glucose + nicorandil group, and high glucose + nicorandil + 5-HD group. Nicorandil prevented high 
glucose-induced cell migration by opening mitoKATP channel. Bars represent mean ± SE. **p < 0.01
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Fig. 6 Effect of εPKC on intimal hyperplasia in balloon-injured carotid arteries. a Representative western blots for εPKC translocation in injured 
carotid artery treated with or without nicorandil or 5-HD. b Quantitative analysis of εPKC translocation. εPKC translocation from the cell soluble (S) to 
the cell particulate fraction (TS) was observed after balloon injury. This translocation was blocked by nicorandil. The effect of nicorandil was reversed 
by 5-HD. c Representative western blots for εPKC protein in the injured carotid artery with or without εPKC siRNA. d Quantitative analysis of εPKC 
protein. εPKC expression in εPKC siRNA delivered group was reduced to 30.41 ± 5.17 % of that in the scramble siRNA delivered group e: Representa-
tive cross-section of carotid artery stained with Elastica van Gieson. f Quantitative analysis of of intima/media ratio. g Quantitative analysis of lumen 
area in DM-injury + scramble siRNA group and DM-injury + εPKC siRNA group. Knockdown of εPKC reduced the intima/media ratio and increased 
lumen area. Bars represent mean ± SE. **p < 0.01
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Fig. 7 Effect of εPKC on inflammation and cell proliferation in balloon injured carotid arteries. a IHC stain of CD 68 was performed in carotid sec-
tions 14 days after balloon injury with or without εPKC siRNA delivery. b Quantitative analysis of CD 68-posotive cells per 104 μm2. c IF staining of 
PCNA and α-SMA was performed in carotid sections 14 days after balloon injury with or without εPKC siRNA delivery. d Quantitative analysis of per-
centage of PCNA-positive cells in intima. Labeling of CD 68 and PCNA were significantly lower in εPKC siRNA delivered group than that in scramble 
siRNA delivered group. Bars represent mean ± SE. ** p < 0.01
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Fig. 8 Effect of εPKC on VSMCs migration induced by high glucose. a Representative western blots for εPKC translocation in VSMCs with or 
without nicorandil or 5-HD. b Quantitative analysis of εPKC translocation. εPKC translocation was induced by high glucose. Nicorandil inhibited the 
increase of εPKC translocation by opening mitoKATP channel. c Representative western blots for εPKC protein in VSMCs with or without εPKC siRNA 
transfection. d Quantitative analysis of εPKC protein. εPKC protein in high-glucose-εPKC siRNA group was reduced to 24.94 ± 7.67 % of that in high-
glucose-scramble siRNA group. e VSMCs migration was assessed by wound healing assay. f Quantitative analysis of percentage of migrated area 
in control group, high glucose + scramble siRNA group, and high glucose + εPKC siRNA group. εPKC siRNA knockdown prevented high glucose-
induced cell migration. Bars represent mean ± SE. *p < 0.05, **p < 0.01
VSMCs proliferation and migration in vitro [7]. Chronic 
hyperglycemia leads to PKC activation and promotes 
VSMCs growth [1]. Nicorandil inhibits the activation of 
εPKC by opening mitoKATP channel in myocardial infarc-
tion rat model [11]. In the present study, we observe 
εPKC activation in balloon-injured arteries in the dia-
betic rats. Nicorandil inhibits this εPKC activation, and 
this inhibition effect was significantly reversed by 5-HD. 
The same εPKC activation trend is also observed in high 
glucose-stimulated VSMCs. In vivo εPKC knockdown is 
achieved by localized delivery of εPKC siRNA and identi-
fied by western blot. Knockdown of εPKC inhibits inti-
mal hyperplasia in diabetic rats. When diabetic rats were 
treated with nicorandil and εPKC siRNA, the lumen area 
is larger than that of rats treated with nicorandil and 
scramble siRNA (data shown in Additional file 1: Figure 
S2). CD 68-positve macrophages and PCNA-positive 
cells in intima are also reduced by localized delivery of 
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Fig. 9 Effect of εPKC on VSMCs proliferation induced by high glucose. a Cell viability was assessed by MTT assay kit. b VSMCs proliferation was 
detected using BrdU proliferation assay kit. 24 h of high glucose induced VSMCs proliferation. εPKC knockdown suppressed the increase of cell 
viability and proliferation induced by high glucose. Bars represent mean ± SE. **p < 0.01
εPKC siRNA. In  vitro εPKC knockdown is achieved by 
transfection of εPKC siRNA in VSMCs. εPKC siRNA 
transfection significantly reduces VSMCs migration area 
and proliferation. Thus, nicorandil inhibited εPKC activa-
tion by opening mitoKATP channel. This is the mechanism 
involved in the beneficial effect of nicorandil on intimal 
hyperplasia after balloon injury in diabetic models. Some 
previous studies reveal that opening of mitoKATP channel 
stimulates εPKC activation. In mouse insulinoma βTC-6 
cells, NNC 55-0321, a novel potassium channel opener, 
promotes εPKC activation. However, NNC 55-0462, 
another novel potassium channel opener, does not pro-
mote εPKC activation [34]. In rat ventricular myocytes, 
diazoxide, a mitoKATP channel opener, induces εPKC 
translocation [35]. εPKC inhibitor cheleryhrine does not 
abolish infarct size-limiting effect of diazoxide in rabbit 
hearts, but it blocks the protective effect of diazoxide 
in rat myocardial infarction [19]. Nicorandil, diazoxide, 
NNC 55-3021 and NNC 55-0462 do not exhibit the same 
effect on εPKC activation in different animal models. The 
discrepancy may reflect species and organ differences in 
regulatory mechanisms of PKC and mitoKATP channel.
In other studies, nicorandil reduces the produc-
tion of reactive oxygen species [13], prevents endothe-
lial dysfunction [36], inhibits VACM-1 expression [31], 
attenuates cardiac sympathetic nerve injury [37], and 
interferences platelet aggregation [36]. These mecha-
nisms may contribute to the inhibition of intimal hyper-
plasia; however, these are beyond the scope of this study. 
Future work is still needed to explore the detailed mecha-
nisms of nicorandil on vascular injury, especially in dia-
betic models.
In summary, our data highlight the inhibitive effect 
of nicorandil on the intimal hyperplasia after balloon 
injury in diabetic rats and propose the underlying 
mechanism. Nicorandil opens mitoKATP channel, inhib-
its the activation of εPKC and prevents inflammation 
and cell proliferation in balloon-injured carotid arteries 
in diabetic rats. In  vitro study reveals that nicorandil 
inhibits high glucose-stimulated VSMCs prolifera-
tion and migration by opening mitoKATP channel and 
inhibiting εPKC activation. No direct evidence of inti-
mal hyperplasia inhibition has been observed in nico-
randil-treated patients in clinical trials. Future clinical 
trials and basic studies should be performed to further 
reveal the protective effect of nicorandil on PCI-related 
complications.
Conclusions
Our present study reveals for the first time that nico-
randil attenuates carotid intimal hyperplasia after balloon 
injury in diabetic rats. Nicorandil inhibits cell prolifera-
tion and CD68-positive inflammatory cell infiltration in 
balloon-injured arteries of diabetic rats. The mechanism 
of the phenomenon involves opening of mitoKATP chan-
nel and inhibiting εPKC activation. In vitro study reveals 
that nicorandil inhibits high glucose-induced VSMCs 
proliferation and migration. These data suggest that 
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nicorandil may have beneficial effect in diabetic patients 
undergoing PCI and reduce PCI-related complications.
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